Syntimmune, Inc. — Form D
Syntimmune, Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2017-06-28. The offering totals $50.0M, of which $18.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-06-28
- Form: D
- Accession: 0001622964-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $50.0M
- Amount sold: $18.0M
- Remaining: $32.0M
- Investors: 3
- Date of first sale: 2017-06-19
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-289606
Issuer
- Name: Syntimmune, Inc.
- CIK: 0001622964
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2013
- Address: 257 PARK AVENUE SOUTH, NEW YORK, NY, 10010
- Phone: 212-498-0011 EXT 301
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Burt Adelman, M.D. | Director | NEW YORK, NY |
| Laurence Blumberg, M.D. | Director | NEW YORK, NY |
| Richard Blumberg, M.D. | Director | NEW YORK, NY |
| DAVID DE GRAAF, PH.D. | Director | CAMBRIDGE, MA |
| Sam Hall, Ph.D. | Director | NEW YORK, NY |
| Seth Harrison, M.D. | Director | NEW YORK, NY |
| Aaron Kantoff | Director | Rockville, MD |
| Laurence Blumberg, M.D. | Executive Officer | NEW YORK, NY |
| DAVID DE GRAAF, PH.D. | Executive Officer | CAMBRIDGE, MA |
| Seth Harrison | Director | Redwood City, CA |
| Geeta Vemuri | Director | Waltham, MA |
| Sam Hall | Director | Seattle, WA |
Other filings by this issuer (1)
More